Organization of the human liver carnitine palmitoyltransferase 1 gene (CPT1A) and identification of novel mutations in hypoketotic hypoglycaemia
Stéphanie Gobin(Inserm), Laure Thuillier(Inserm), Jean‐Paul Bonnefont(Inserm), Fatima Djouadi(Délégation Paris 5), M. Ferrec(Hôpital Necker-Enfants Malades), Stephen D. Cederbaum(Neuropsychiatric Research Institute), A. J. Green(Birmingham Children's Hospital), Hidayeth Rostane(Hôpital Necker-Enfants Malades), Jean‐Marie Saudubray, Claude Mugnier(Inserm), George F. Gray(Kingston Health Sciences Centre), France Demaugre(Inserm), William L. Nyhan(National Institutes of Health), Richard Haas(Rady Children's Hospital-San Diego), Carina Prip‐Buus(Centre National de la Recherche Scientifique), Jean Girard(Centre National de la Recherche Scientifique), William R. Wilcox(Emory University)
Cited by 53
Related Papers
Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society
|Genetics in Medicine|2014|605
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
|Nephrology Dialysis Transplantation|2009|366
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
|Journal of Medical Genetics|2015|363